AMRN:NSD-Amarin Corporation plc (USD)

EQUITY | Drug Manufacturers - General | NASDAQ Global Market

Last Closing

USD 11.36

Change

+0.25 (+2.25)%

Market Cap

USD 0.91B

Volume

0.04M

Analyst Target

USD 13.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.49 (+0.70%)

USD 218.30B
AMGN Amgen Inc

+5.14 (+1.85%)

USD 151.21B
SNY Sanofi ADR

+0.36 (+0.69%)

USD 126.38B
GILD Gilead Sciences Inc

+2.67 (+2.46%)

USD 122.21B
BIIB Biogen Inc

+5.22 (+4.09%)

USD 17.35B
GRFS Grifols SA ADR

+0.18 (+2.20%)

USD 5.91B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

+0.40 (+7.62%)

N/A
SCLXW Scilex Holding Company

-0.01 (-12.33%)

N/A

ETFs Containing AMRN

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2,242.27% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,242.27% 100% F 100% F
Trailing 12 Months  
Capital Gain 1,252.06% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,252.06% 100% F 100% F
Trailing 5 Years  
Capital Gain 66.33% 100% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.33% 100% F 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 14.49% 100% F 73% C
Dividend Return 14.49% 100% F 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 220.44% 10% F 10% F
Risk Adjusted Return 6.57% 60% D- 43% F
Market Capitalization 0.91B 25% F 51% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 73.50 14% 14%
Price/Book Ratio 0.44 100% 90%
Price / Cash Flow Ratio -7.46 100% 82%
Price/Free Cash Flow Ratio -5.80 100% 87%
Management Effectiveness  
Return on Equity -15.83% 25% 45%
Return on Invested Capital -16.72% 25% 34%
Return on Assets -4.56% 25% 41%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector